Actualités

Semiconductor metrology and energy research orders surge over 50% organically.

Moby summary of Bruker Corporation's Q2 2026 earnings call

Bruker Corp (BRKR) posts 5.2% revenue growth and 53% EPS jump, driven by strong biopharma and semiconductor orders despite U.S. academic weakness.

Bruker (NASDAQ:BRKR) reported second-quarter revenue growth and expanded profitability as demand improved for scientific instruments, particularly in biopharma and several “deep tech” markets including semiconductor metrology, security detection and energy research. Second-quarter reported revenue

Bruker (BRKR) delivered earnings and revenue surprises of +28.95% and -2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Scientific instrument company Bruker (NASDAQ:BRKR) will be announcing earnings results this Tuesday before market open. Here’s what to look for.

In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains.

Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that management said came in “well ahead of expectations,” even as the company continued to face pressure from U.S. academic demand weakness as well as tariff and currency headwinds. President and CEO Frank Laukien told investors that while y

Bruker (BRKR) delivered earnings and revenue surprises of +33.62% and +2.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?